logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Anticholinergic class drugs

    FiltersReset Filters
    8 results

    • anoro ellipta

      (umeclidinium bromide and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

    • bevespi aerosphere

      (Glycopyrrolate and formoterol fumarate)
      AstraZeneca Pharmaceuticals LP
      Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or for asthma treatment.

    • cuvposa

      (glycopyrrolate)
      Merz Pharmaceuticals, LLC
      Usage: CUVPOSA is indicated for reducing chronic severe drooling in children aged 3 to 16 with neurologic conditions such as cerebral palsy.

    • incruse ellipta

      (umeclidinium)
      GlaxoSmithKline LLC
      Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

    • qbrexza

      (glycopyrronium)
      Journey Medical Corporation
      Usage: Qbrexza is indicated for the topical treatment of primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older.

    • stiolto respimat

      (tiotropium bromide and olodaterol)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: STIOLTO RESPIMAT is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD deteriorations or for the treatment of asthma.

    • trelegy ellipta

      (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: TRELEGY ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 and older. It is not intended for the relief of acute bronchospasm.

    • yupelri

      (revefenacin)
      Mylan Specialty L.P.
      Usage: YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).